Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Frontiers in Oncology
|
December 6, 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma
Ahmed Bilal Khalid, Christos Fountzilas, Heather N Burney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 20, 2008
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study
Shadia Jalal, Rafat Ansari, Ramaswamy Govindan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 25, 2010
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group
Shadia Jalal, Pablo Bedano, Lawrence Einhorn, et al.
Journal for Immunotherapy of Cancer
|
May 14, 2026
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer
Rachel T Gonzalez, Reena Datta, Sadiq Rehmani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2009
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group
Shadia Jalal, David Waterhouse, Martin J Edelman, et al.
Elife
|
July 11, 2022
Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
Andrea M Chambers, Kyle B Lupo, Jiao Wang, et al.
Journal of Thoracic Disease
|
July 14, 2026
Real world comparative outcomes of adjuvant carboplatin versus cisplatin-based chemotherapy in stage IB-IIIA non-small cell lung cancer: a propensity-weighted analysis
Molly Tokaz, Brendan T Heiden, Daniel B Eaton, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2025
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
Greg Durm, Hirva Mamdani, Sandra Althouse, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer
Nuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
JCO Oncology Practice
|
June 18, 2026
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis
Garth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Frontiers in Oncology
|
December 6, 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma
Ahmed Bilal Khalid, Christos Fountzilas, Heather N Burney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 20, 2008
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study
Shadia Jalal, Rafat Ansari, Ramaswamy Govindan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 25, 2010
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group
Shadia Jalal, Pablo Bedano, Lawrence Einhorn, et al.
Journal for Immunotherapy of Cancer
|
May 14, 2026
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer
Rachel T Gonzalez, Reena Datta, Sadiq Rehmani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2009
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group
Shadia Jalal, David Waterhouse, Martin J Edelman, et al.
Elife
|
July 11, 2022
Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
Andrea M Chambers, Kyle B Lupo, Jiao Wang, et al.
Journal of Thoracic Disease
|
July 14, 2026
Real world comparative outcomes of adjuvant carboplatin versus cisplatin-based chemotherapy in stage IB-IIIA non-small cell lung cancer: a propensity-weighted analysis
Molly Tokaz, Brendan T Heiden, Daniel B Eaton, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2025
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
Greg Durm, Hirva Mamdani, Sandra Althouse, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer
Nuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
JCO Oncology Practice
|
June 18, 2026
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis
Garth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, et al.
Page
of 3